Posted by Michael Wonder on 06 Feb 2025
Serplulimab approved in the EU for first-line treatment of extensive-stage small cell lung cancer
5 February 2025 - Serplulimab is the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of extensive stage small-cell lung cancer.
Shanghai Henlius Biotech announced that its anti-PD-1 monoclonal antibody Hetronifly has been officially approved by the European Commission for use in combination with carboplatin and etoposide as a first-line treatment of adult patients with extensive stage small-cell lung cancer.
